Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Yagyu

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Cancer Immunology, Immunotherapy : CII|October 10, 2022
Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangementMasaya Suematsu, Shigeki Yagyu, Hideki Yoshida, et al.
Japanese Journal of Clinical Oncology|May 5, 2019
A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patientsTomoko Iehara, Shigeki Yagyu, Takahiro Gotoh, et al.
Molecular Therapy. Methods & Clinical Development|April 26, 2021
Autologous antigen-presenting cells efficiently expand <i>piggyBac</i> transposon CAR-T cells with predominant memory phenotypeKayoko Nakamura, Shigeki Yagyu, Shogo Hirota, et al.
European Journal of Haematology|May 7, 2005
Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantationShigeki Yagyu, Hiroshi Kuroda, Atsushi Fujiki, et al.
Clinical & Translational Immunology|June 14, 2021
A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cellsShigeki Yagyu, Hidemi Mochizuki, Kumiko Yamashima, et al.
Clinical & Translational Immunology|November 30, 2020
Autologous non-human primate model for safety assessment of <i>piggyBac</i> transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptorHirokazu Morokawa, Shigeki Yagyu, Aiko Hasegawa, et al.
Japanese Journal of Clinical Oncology|May 22, 2016
Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosisTomoko Iehara, Shigeki Yagyu, Kunihiko Tsuchiya, et al.
Anticancer Research|May 29, 2023
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular ImmunotherapyMasafumi Iguchi, Shigeki Yagyu, Kosuke Kambe, et al.
Oncology Reports|October 27, 2018
OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cellsChihiro Tomoyasu, Ken Kikuchi, Daisuke Kaneda, et al.
Molecular Therapy Oncolytics|April 5, 2021
Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcomaHiroshi Kubo, Shigeki Yagyu, Kayoko Nakamura, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Cancer Immunology, Immunotherapy : CII|October 10, 2022
Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangementMasaya Suematsu, Shigeki Yagyu, Hideki Yoshida, et al.
Japanese Journal of Clinical Oncology|May 5, 2019
A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patientsTomoko Iehara, Shigeki Yagyu, Takahiro Gotoh, et al.
Molecular Therapy. Methods & Clinical Development|April 26, 2021
Autologous antigen-presenting cells efficiently expand <i>piggyBac</i> transposon CAR-T cells with predominant memory phenotypeKayoko Nakamura, Shigeki Yagyu, Shogo Hirota, et al.
European Journal of Haematology|May 7, 2005
Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantationShigeki Yagyu, Hiroshi Kuroda, Atsushi Fujiki, et al.
Clinical & Translational Immunology|June 14, 2021
A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cellsShigeki Yagyu, Hidemi Mochizuki, Kumiko Yamashima, et al.
Clinical & Translational Immunology|November 30, 2020
Autologous non-human primate model for safety assessment of <i>piggyBac</i> transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptorHirokazu Morokawa, Shigeki Yagyu, Aiko Hasegawa, et al.
Japanese Journal of Clinical Oncology|May 22, 2016
Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosisTomoko Iehara, Shigeki Yagyu, Kunihiko Tsuchiya, et al.
Anticancer Research|May 29, 2023
Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular ImmunotherapyMasafumi Iguchi, Shigeki Yagyu, Kosuke Kambe, et al.
Oncology Reports|October 27, 2018
OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cellsChihiro Tomoyasu, Ken Kikuchi, Daisuke Kaneda, et al.
Molecular Therapy Oncolytics|April 5, 2021
Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcomaHiroshi Kubo, Shigeki Yagyu, Kayoko Nakamura, et al.
Pageof 7